Alpha-3 beta-2 nicotinic receptor
Type of human nicotinic acetylcholine receptor
The alpha-3 beta-2 nicotinic receptor, also known as the α3β2 receptor, is a type of nicotinic acetylcholine receptor, consisting of α3 and β2 subunits.
It occurs alongside the more common α3β4 nicotinic receptor in autonomic ganglia, and as an facilitatory presynaptic autoreceptor at the neuromuscular junction (NMJ). At the NMJ, it is involved in upregulation of ACh release during high-frequency stimulation. Nicotine, a component of tobacco and the namesake agonist of the receptor, has been found to increase its concentration. Blockage of this receptor in the presence of a partial postsynaptic neuromuscular block is thought to produce the characteristic tetanic fade caused by non-depolarizing neuromuscular blockers.
The receptor is classified as an allosteric enzyme that is generally activated by the natural agonistacetylcholine, however it may also be activated by external agonists such as nicotine and blocked by toxins such as bungarus toxin 3.1. The main role of the receptor is to allow the reuptake of the neurotransmitter acetylcholine. Because it is a receptor involved in mechanisms including the neurotransmitter acetylcholine it is synthesized in the brain. However, α3β2 receptors synthesized in different locations of the brain may have differing regulatory properties. this is due to the cytoplasmic region in which the receptor is being formulated.
Begin with the source’s own compact description: “Alpha-3 beta-2 nicotinic receptor” is type of human nicotinic acetylcholine receptor. The dossier treats that line as a proposition to test through Alpha-3, beta-2 and nicotinic, not as a finished interpretation.
Why this record matters
The phrase “type of human nicotinic acetylcholine receptor” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jun 5, 2026. The linked authority identifier is Q18351422. None of the 0 selected statements returned an explicit reference.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Alpha-3 beta-2 nicotinic receptor”, its source revision and the description used here.
- Expand the search: follow Alpha-3 beta-2 nicotinic receptor primary sources, Alpha-3 beta-2 nicotinic receptor archive and Alpha-3 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Alpha-3 beta-2 nicotinic receptor”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Alpha-3 beta-2 nicotinic receptor” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.